EODData

MEMBERSHIP REGISTER LOG IN

FRA, IM8N: Insmed Incorporated

21 Nov 2025
LAST:

172.0

CHANGE:
 4.00		OPEN:
172.0		HIGH:
177.0		ASK:
0.0		VOLUME:
145
CHG(%):
2.27		PREV:
176.0		LOW:
172.0		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Nov 25172.0177.0172.0172.0145
20 Nov 25176.0176.0176.0176.00
19 Nov 25172.0175.0172.0175.00
18 Nov 25168.0168.0168.0168.00
17 Nov 25165.0169.0165.0167.00
13 Nov 25166.0169.0166.0169.00
12 Nov 25166.0169.0166.0169.0334
11 Nov 25166.0166.0166.0166.0134
10 Nov 25167.0168.0167.0168.050
07 Nov 25160.0160.0158.0158.00

PROFILE

Name:Insmed Incorporated
About:Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:700 US Highway 202/206, Bridgewater, NJ, United States, 08807
Website:https://www.insmed.com
ISIN:US4576693075
LEI:529900Q55QAG41CCAC11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-28.90 
Forward P/E:-51.55 
PEG Ratio:2.34 
Price to Sales:79.20 
Price to Book:37.32 
Profit Margin:-2.65 
Operating Margin:-1.84 
Return on Assets:-0.28 
Return on Equity:-1.66 
Revenue:387.97M 
Shares:211.38M 
Market Cap:36.357B 

TECHNICAL INDICATORS

MA5:171.600.2%
MA10:168.801.9%
MA20:160.307.3%
MA50:137.9024.7%
MA100:114.9649.6%
MA200:91.5587.9%
STO9:54.55
STO14:73.68
RSI14:52.08
WPR14:-22.22
MTM14:6.00
ROC14:0.04 
ATR:3.86 
Week High:177.002.9%
Week Low:165.004.2%
Month High:177.002.9%
Month Low:137.0087.9%
Year High:177.002.9%
Year Low:57.17200.9%
Volatility:18.99 

RECENT SPLITS

Date Ratio
03 Mar 20111-10